H-1B sponsorship profile: International AIDS Vaccine Initiative (IAVI). Across U.S. Department of Labor LCA disclosures, International AIDS Vaccine Initiative (IAVI) filed 10 Labor Condition Applications covering 10 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (10 certified of 10 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on International AIDS Vaccine Initiative (IAVI)’s H-1B petitions range from $72,800 at the low end to $225,000 at the high end, with a petition-weighted average of $151,232. That range reflects the mix of occupations the company sponsors, led by Medical Director, Early-Stage Clinical Development (2 petitions at $225,000 avg), followed by Director, Regulatory Affairs and Specialist, Talent Development. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. International AIDS Vaccine Initiative (IAVI) is headquartered in New York, NY under NAICS code 54199, and places H-1B workers across 5 states, most heavily in CA, NJ, TX. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where International AIDS Vaccine Initiative (IAVI) ranks. By H-1B petition volume, International AIDS Vaccine Initiative (IAVI) is #16,610 of 119,880 employers nationally and #1,422 of 14,719 employers headquartered in NY. Both ranks are computed live from the same underlying petition counts, not a separate estimate.